secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2022-05-17T23:59:59+00:00
Accession:  0001140361-22-019590
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive CEO Keith Kendall departs; COO Daniel Barber named President & CEO
----------------------------------------------------------------------------

- Keith Kendall leaves as President, CEO, and Board member effective May 17, 2022.
- Daniel Barber, former COO (since May 2019), appointed President, CEO, and Class I Director.
- Kendall receives severance: $262,500 accelerated first three installments plus monthly payments, and $10,000/month consulting fee through Dec 2022.
- Kendall will serve as consultant to assist in management transition through end of 2022.
- Company states Kendall's departure is unrelated to strategy, operations, or financial condition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000114036122019590/0001140361-22-019590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000114036122019590/brhc10037837_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-019590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer